Bio-Rad Laboratories, Inc. Class A Common Stock vs Krispy Kreme Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.02B), while Krispy Kreme Inc trades at $3.36 (market cap $599.95M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 13.4× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays a 3.47% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | DNUT | |
|---|---|---|
Market Cap | $8.02B | $599.95M |
Sector | Health | Consumer Staples |
52-Week High | $339.75 | $4.70 |
52-Week Low | $241.71 | $2.92 |
Enterprise Value | $7.84B | $1.80B |
Dividend Yield | — | 3.47% |
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →